Top drug development exec from 23andMe departs

Consumer genetics company 23andMe has lost its chief scientific officer, Richard Scheller, PhD, who was responsible for finding and developing new drugs, according to STAT.

Dr. Scheller, who served at 23andMe for four years, has left the company to join biotechnology company BridgeBio as chairman of research and development. He will remain on 23andMe's board of directors. 

Kenneth Hillan, 23andMe's head of therapeutics, will take over Dr. Scheller's responsibilities but not his title, according to the report. 

23andMe announced in March 2015 that it would begin to develop drugs. According to its website, the company is working on treatments for cancer and diseases that affect the skin, lungs and heart. 

Read the full report here

Copyright © 2024 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


Featured Whitepapers

Featured Webinars